Pseudomonas aeruginosa and Its Resistance

HAI Pathogens and Antimicrobial Resistance Report, 2018-2021. Centers for Disease Control and Prevention. https://www.cdc.gov/nhsn/hai-report/data-tables-adult/index.html. Published 2023.(Accessed on November 12, 2024).

Moradali MF, Ghods S, Rehm BH. Pseudomonas aeruginosa lifestyle: A paradigm for adaptation, survival, and persistence. Front Cell Infect Microbiol. 2017:7:39.

Apisarnthanarak A, Hsu LY, Khawcharoen porn T, Mundy LM. Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings? Expert Rev Anti Infect Ther. 2013;11:147-157.

Peri AM, Doi Y, Potoski BA, Harris PN, Paterson DL, Righi E. Antimicrobial treatment challenges in the era of carbapenem resistance. Diagn Microbiol Infect Dis. 2019;94:413-425.

Khawcharoenporn T, Chuncharunee A, Maluangnon C, Taweesakulvashra T, Tiamsak P. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia. Int J Antimicrob Agents. 2018;52:828-834.

Chemical Disinfectants. Centers for Disease Control and Prevention. https://www.cdc.gov/infection-control/hcp/disinfection-sterilization/chemicaldisinfectants.html#:~:text=Pseudomonas%20aeruginosa%20was%20killed%20in,from%2040%25%20to%2000%25. Published 2023.(Accessed on November 14, 2024).

Meyer B, Cookson B. Does microbial resistance or adaptation to biocides create a hazard in infection prevention and control? J Hosp Infect. 2010;76:200-205.

Tag ElDein MA, Yassin AS, El-Tayeb O, Kashef MT. Chlorhexidine leads to the evolution of antibiotic-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2021;40:2349-2361.